Physician profile
James E Needell
NPI 1417988825
$2,968.86
in general payments reported to CMS, 2019-2025
33 companies · $198 in 2025
The $198 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,506 · 2020: $760 · 2021: $505 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $197.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $605.53 | 2019-2021 | |
| Lilly USA, LLC | $340.39 | 2019-2025 | Zepbound, Mounjaro |
| Amarin Pharma, INC. | $252.71 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $239.33 | 2019-2025 | Breztri |
| Novo Nordisk INC | $213.66 | 2019-2025 | Ozempic |
| Amgen INC. | $138.84 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.17 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $75.37 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.56 | 2020-2021 | |
| Abbvie INC. | $71.91 | 2021-2025 | |
| Mylan Specialty L.P. | $70.25 | 2019-2020 | |
| Pfizer INC. | $69.19 | 2019-2021 | |
| Eisai INC. | $65.65 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $65.28 | 2020-2021 | |
| Glaxosmithkline, LLC. | $65.07 | 2019-2025 | Arexvy, Shingrix |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $63.01 | 2019 | |
| Sunovion Pharmaceuticals INC. | $60.32 | 2019 | |
| Gilead Sciences, INC. | $48.93 | 2019 | |
| Sanofi-Aventis U.S. LLC | $43.63 | 2019 | |
| Scilex Pharmaceuticals INC. | $43.15 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $39.78 | 2019 | |
| Allergan, INC. | $25.75 | 2019 | |
| Advanced Respiratory, INC | $25.37 | 2019 | |
| Masimo Corporation | $20.11 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.67 | 2025 | |
| Axsome Therapeutics, INC. | $19.15 | 2025 | Auvelity |
| Philips North America LLC | $18.35 | 2019 | |
| Ibsa Pharma INC. | $18.19 | 2020 | |
| Corcept Therapeutics | $17.24 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $14.71 | 2021 | |
| Vifor Pharma, INC. | $14.59 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Needell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.